Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, pharmacokinetics, and pharmacodynamic effects of a novel
anti-cancer drug, GZ17-6.02 administered to patients with advanced solid tumors or lymphoma,
which have progressed after receiving standard/approved therapy or where there is no approved
therapy.